Chemical Namepacritinib
Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
CompanyCTI BioPharma
Approval Year2022


  • For the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × (10)^9/L.
Last updated on 5/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vonjo (pacritinib) Prescribing Information. 2022CTI BioPharma Corp., Seattle WA